v3.26.3
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS
 9 Months Ended
Sep. 30, 2026
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS  
CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

NOTE 16 – CONDENSED CONSOLIDATING BALANCE SHEET AND STATEMENT OF OPERATIONS

 

A condensed consolidating balance sheet of the Company as of September 30, 2026 follows:

 

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Current Assets

 

$-

 

 

$360

 

 

$76,499

 

 

$-

 

 

$502,493

 

 

$-

 

 

$579,352

 

Investment in subsidiaries and variable interest entity (VIE)

 

 

(2,181,987)

 

 

930,000

 

 

 

-

 

 

 

-

 

 

 

547,876

 

 

 

704,111

 

 

 

-

 

Intercompany receivables

 

 

-

 

 

 

-

 

 

 

464,474

 

 

 

-

 

 

 

954,508

 

 

 

(1,418,982)

 

 

-

 

Other assets

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

72,040

 

 

 

(1)

 

 

72,039

 

Total Assets

 

$(2,181,987)

 

$930,360

 

 

 

540,973

 

 

 

-

 

 

 

2,076,917

 

 

 

(714,872)

 

 

651,391

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total current liabilities

 

$-

 

 

$150,000

 

 

$54,309

 

 

$-

 

 

$3,345,118

 

 

$-

 

 

$3,549,427

 

Intercompany payables

 

 

-

 

 

 

-

 

 

 

46,770

 

 

 

-

 

 

 

1,372,213

 

 

 

(1,418,983)

 

 

-

 

Other liabilities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Total Liabilities

 

 

-

 

 

 

150,000

 

 

 

101,079

 

 

 

-

 

 

 

4,717,331

 

 

 

(1,418,983)

 

 

3,549,427

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shareholders' Deficit:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital stock and additional paid in capital

 

 

-

 

 

 

1,569,229

 

 

 

888,731

 

 

 

-

 

 

 

4,852,163

 

 

 

(1,670,820)

 

 

5,639,303

 

Accumulated deficit

 

 

(2,181,987)

 

 

(788,869)

 

 

(448,837)

 

 

-

 

 

 

(7,404,231)

 

 

2,374,931

 

 

 

(8,448,993)

Accumulated other comprehensive income (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(40,260)

 

 

-

 

 

 

(40,260)

Non—controlling interests

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(48,086)

 

 

-

 

 

 

(48,086)

Total Deficit

 

 

(2,181,987)

 

 

780,360

 

 

 

439,894

 

 

 

-

 

 

 

(2,640,414)

 

 

704,111

 

 

 

(2,898,036)

Total Liabilities and Shareholders' Equity

 

$(2,181,987)

 

$930,360

 

 

$540,973

 

 

$-

 

 

$2,076,917

 

 

$(714,872)

 

$651,391

 

A condensed consolidating statement of operations of the Company for the nine months ended September 30, 2026 follows:

 

 

 

Yubo International Biotech Limited (Parent Company)

 

 

Platinum (Cayman Island) and Platinum HK

(Cayman Island)

 

 

Yubo

Global

 

 

Yubo Chengdu

(WFOE)

 

 

Yubo Beijing (VIE

Subsidiaries)

 

 

Elimination

 

 

Consolidated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales of product and services

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Cost of goods and services sold

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Gross profit

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Total operating expenses

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

731,522

 

 

 

-

 

 

 

731,522

 

Loss from operations

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(731,522 )

 

 

-

 

 

 

(731,522 )

Other income (expense)

 

 

-

 

 

 

-

 

 

 

1

 

 

 

-

 

 

 

(35,952 )

 

 

-

 

 

 

(35,951 )

Equity in net loss of subsidiaries and variable interest entity (VIE)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Net Loss

 

$-

 

 

$-

 

 

$1

 

 

$-

 

 

$(767,474 )

 

$-

 

 

$(767,473 )